When adjusting for other possible risk factors, reduced IGF-1 levels were independent predictor for unfavorable functional outcome and mortality, and serum IGF-1 levels ≤130 ng/mL were associated with an 3.31-fold increase in AIS patients with unfavorable functional outcome. Here, IGF1 is linked to androgen insensitivity syndrome.